Lance Berry Sells 5,178 Shares of Artivion (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) EVP Lance Berry sold 5,178 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $38.02, for a total value of $196,867.56. Following the transaction, the executive vice president directly owned 176,269 shares in the company, valued at $6,701,747.38. This trade represents a 2.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Artivion Price Performance

Shares of AORT stock opened at $38.41 on Thursday. The firm has a market cap of $1.84 billion, a price-to-earnings ratio of 192.06 and a beta of 1.60. Artivion, Inc. has a 12 month low of $21.97 and a 12 month high of $48.25. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49. The stock has a 50-day moving average price of $41.42 and a 200 day moving average price of $42.92.

Artivion (NYSE:AORT) last issued its earnings results on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.03. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The company had revenue of $118.30 million for the quarter, compared to analyst estimates of $116.42 million. The company’s revenue for the quarter was up 19.2% compared to the same quarter last year. Research analysts expect that Artivion, Inc. will post 0.37 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on AORT. Oppenheimer reiterated an “outperform” rating and set a $50.00 target price on shares of Artivion in a research report on Friday, November 7th. Citizens Jmp lifted their price objective on Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research note on Friday, November 7th. Needham & Company LLC reissued a “buy” rating and issued a $58.00 target price on shares of Artivion in a research note on Monday, February 2nd. Canaccord Genuity Group reduced their target price on Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a report on Friday, February 13th. Finally, Wall Street Zen cut Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.97.

Key Artivion News

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Analysts remain constructive — consensus rating is “Moderate Buy” with several buy/outperform notes and mid‑to‑high price targets that support investor demand. Artivion Receives Consensus Rating
• Positive Sentiment: Management will present at the Oppenheimer Healthcare MedTech & Services Conference (virtual fireside chat), giving the company an opportunity to update investors on growth drivers, product progress and commercial milestones. Conferences can re‑ignite buying interest if guidance or pipeline commentary is favorable. Artivion to Participate in Oppenheimer Conference
• Positive Sentiment: Large institutional investors have been adding exposure (Invesco and others increased stakes), which can provide a steady bid and signals confidence from professional investors. MarketBeat – Artivion Institutional Activity
• Neutral Sentiment: Recent quarterly results beat revenue and EPS estimates and showed strong year‑over‑year revenue growth; that supports the bull case but may already be reflected in the share price and analyst upgrades. MarketBeat – Artivion Earnings Summary
• Negative Sentiment: Multiple senior insiders sold stock over March 2–4 (including the CEO and several EVPs/SVPs). A concentrated block of insider sales often weighs on sentiment even when executives retain large holdings — markets can interpret it as opportunistic liquidity or as a signal of limited near‑term confidence. Insider Trades Alert

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Squarepoint Ops LLC acquired a new stake in Artivion during the 2nd quarter worth approximately $664,000. Kennedy Capital Management LLC increased its position in shares of Artivion by 20.8% during the second quarter. Kennedy Capital Management LLC now owns 367,762 shares of the company’s stock worth $11,437,000 after acquiring an additional 63,205 shares in the last quarter. Sio Capital Management LLC raised its holdings in shares of Artivion by 31.0% during the second quarter. Sio Capital Management LLC now owns 158,736 shares of the company’s stock worth $4,937,000 after acquiring an additional 37,558 shares during the period. Atria Investments Inc bought a new stake in Artivion in the 2nd quarter valued at $244,000. Finally, Osterweis Capital Management Inc. bought a new position in Artivion during the 2nd quarter worth about $3,750,000. 86.37% of the stock is owned by institutional investors and hedge funds.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.